PROF
Profound MedicalPROF
PROF
About: Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Employees: 131
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
164% more call options, than puts
Call options by funds: $29K | Put options by funds: $11K
37% more capital invested
Capital invested by funds: $75M [Q3] → $103M (+$28.1M) [Q4]
18% more funds holding
Funds holding: 44 [Q3] → 52 (+8) [Q4]
7.4% more ownership
Funds ownership: 38.47% [Q3] → 45.86% (+7.4%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PROF.
Financial journalist opinion
Based on 5 articles about PROF published over the past 30 days
Neutral
PRNewsWire
7 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Seeking Alpha
5 days ago
Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript
Profound Medical Corporation (NASDAQ:PROF ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Stephen Kilmer – IR Rashed Dewan - CFO Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat – CEO Conference Call Participants John Baugh - Stifel Michael Freeman - Raymond James Operator Thank you for standing by and welcome to the Profound Medical Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
5 days ago
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.42 per share a year ago.
Negative
Zacks Investment Research
1 week ago
Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
3 weeks ago
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025.
Neutral
GlobeNewsWire
2 months ago
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16 th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2024.
Positive
Zacks Investment Research
2 months ago
Does Profound Medical (PROF) Have the Potential to Rally 100.13% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 100.1% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
2 months ago
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA.
Neutral
GlobeNewsWire
3 months ago
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, before deducting the underwriting discounts and commissions and other offering expenses payable by Profound, of approximately US$40.25 million.
Neutral
GlobeNewsWire
3 months ago
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR
Charts implemented using Lightweight Charts™